<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39460266</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>28</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2076-393X</ISSN><JournalIssue CitedMedium="Print"><Volume>12</Volume><Issue>10</Issue><PubDate><Year>2024</Year><Month>Sep</Month><Day>26</Day></PubDate></JournalIssue><Title>Vaccines</Title><ISOAbbreviation>Vaccines (Basel)</ISOAbbreviation></Journal><ArticleTitle>Safety and Immunogenicity Study of a Bivalent Vaccine for Combined Prophylaxis of COVID-19 and Influenza in Non-Human Primates.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">1099</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/vaccines12101099</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Influenza and SARS-CoV-2 viruses are two highly variable pathogens. We have developed a candidate bivalent live vaccine based on the strain of licensed A/Leningrad/17-based cold-adapted live attenuated influenza vaccine (LAIV) of H3N2 subtype, which expressed SARS-CoV-2 immunogenic T-cell epitopes. A cassette encoding fragments of S and N proteins of SARS-CoV-2 was inserted into the influenza NA gene using the P2A autocleavage site. In this study, we present the results of preclinical evaluation of the developed bivalent vaccine in a non-human primate model.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Rhesus macaques (<i>Macaca mulatta</i>) (n = 3 per group) were immunized intranasally with 7.5 lg EID<sub>50</sub> of the LAIV/CoV-2 bivalent vaccine, a control non-modified H3N2 LAIV or a placebo (chorioallantoic fluid) using a sprayer device, twice, with a 28-day interval. The blood samples were collected at days 0, 3, 28 and 35 for hematological and biochemical assessment. Safety was also assessed by monitoring body weight, body temperature and clinical signs of the disease. Immune responses to influenza virus were assessed both by determining serum antibody titers in hemagglutination inhibition assay, microneutralization assay and IgG ELISA. T-cell responses were measured both to influenza and SARS-CoV-2 antigens using ELISPOT and flow cytometry. Three weeks after the second immunization, animals were challenged with 10<sup>5</sup> PFU of Delta SARS-CoV-2. The body temperature, weight and challenge virus shedding were monitored for 5 days post-challenge. In addition, virus titers in various organs and histopathology were evaluated on day 6 after SARS-CoV-2 infection.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">There was no toxic effect of the immunizations on the hematological and coagulation hemostasis of animals. No difference in the dynamics of the average weight and thermometry results were found between the groups of animals. Both LAIV and LAIV/CoV-2 variants poorly replicated in the upper respiratory tract of rhesus macaques. Nevertheless, despite this low level of virus shedding, influenza-specific serum IgG responses were detected in the group of monkeys immunized with the LAIV/CoV-2 bivalent but not in the LAIV group. Furthermore, T-cell responses to both influenza and SARS-CoV-2 viruses were detected in the LAIV/CoV-2 vaccine group only. The animals were generally resistant to SARS-CoV-2 challenge, with minimal virus shedding in the placebo and LAIV groups. Histopathological changes in vaccinated animals were decreased compared to the PBS group, suggesting a protective effect of the chimeric vaccine candidate.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The candidate bivalent vaccine was safe and immunogenic for non-human primates and warrants its further evaluation in clinical trials.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Stepanova</LastName><ForeName>Ekaterina</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0002-8670-8645</Identifier><AffiliationInfo><Affiliation>Institute of Experimental Medicine, Saint-Petersburg 197022, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Isakova-Sivak</LastName><ForeName>Irina</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Institute of Experimental Medicine, Saint-Petersburg 197022, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Matyushenko</LastName><ForeName>Victoria</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Institute of Experimental Medicine, Saint-Petersburg 197022, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mezhenskaya</LastName><ForeName>Daria</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0001-6922-7682</Identifier><AffiliationInfo><Affiliation>Institute of Experimental Medicine, Saint-Petersburg 197022, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kudryavtsev</LastName><ForeName>Igor</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Institute of Experimental Medicine, Saint-Petersburg 197022, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kostromitina</LastName><ForeName>Arina</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0001-5432-0171</Identifier><AffiliationInfo><Affiliation>Institute of Experimental Medicine, Saint-Petersburg 197022, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chistiakova</LastName><ForeName>Anna</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0001-9541-5636</Identifier><AffiliationInfo><Affiliation>Institute of Experimental Medicine, Saint-Petersburg 197022, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rak</LastName><ForeName>Alexandra</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Institute of Experimental Medicine, Saint-Petersburg 197022, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bazhenova</LastName><ForeName>Ekaterina</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0003-3280-556X</Identifier><AffiliationInfo><Affiliation>Institute of Experimental Medicine, Saint-Petersburg 197022, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prokopenko</LastName><ForeName>Polina</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Institute of Experimental Medicine, Saint-Petersburg 197022, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kotomina</LastName><ForeName>Tatiana</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0001-9999-089X</Identifier><AffiliationInfo><Affiliation>Institute of Experimental Medicine, Saint-Petersburg 197022, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Donina</LastName><ForeName>Svetlana</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Institute of Experimental Medicine, Saint-Petersburg 197022, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Novitskaya</LastName><ForeName>Vlada</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Institute of Experimental Medicine, Saint-Petersburg 197022, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sivak</LastName><ForeName>Konstantin</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0003-4064-5033</Identifier><AffiliationInfo><Affiliation>Smorodintsev Research Institute of Influenza, Saint-Petersburg 197376, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Karal-Ogly</LastName><ForeName>Dzhina</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Center of Preclinical Research, Research Institute of Medical Primatology, Sochi 354376, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rudenko</LastName><ForeName>Larisa</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Institute of Experimental Medicine, Saint-Petersburg 197022, Russia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>21-75-30003</GrantID><Agency>Russian Science Foundation</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Vaccines (Basel)</MedlineTA><NlmUniqueID>101629355</NlmUniqueID><ISSNLinking>2076-393X</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">bivalent vaccine</Keyword><Keyword MajorTopicYN="N">influenza</Keyword><Keyword MajorTopicYN="N">non-human primates</Keyword><Keyword MajorTopicYN="N">preclinical study</Keyword><Keyword MajorTopicYN="N">rhesus monkeys</Keyword><Keyword MajorTopicYN="N">virus-vectored vaccine</Keyword></KeywordList><CoiStatement>Authors I.-I.S., E.S., D.M., V.M. and L.R. have patent #RU 2782531 issued to FSBSI “Institute of experimental medicine”. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>8</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>9</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>26</Day><Hour>19</Hour><Minute>25</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>26</Day><Hour>19</Hour><Minute>24</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>26</Day><Hour>1</Hour><Minute>25</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>26</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39460266</ArticleId><ArticleId IdType="pmc">PMC11511058</ArticleId><ArticleId IdType="doi">10.3390/vaccines12101099</ArticleId><ArticleId IdType="pii">vaccines12101099</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Tan A.T., Linster M., Tan C.W., Le Bert N., Chia W.N., Kunasegaran K., Zhuang Y., Tham C.Y.L., Chia A., Smith G.J.D., et al. Early Induction of Functional SARS-CoV-2-Specific T Cells Associates with Rapid Viral Clearance and Mild Disease in COVID-19 Patients. Cell Rep. 2021;34:108728. doi: 10.1016/j.celrep.2021.108728.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2021.108728</ArticleId><ArticleId IdType="pmc">PMC7826084</ArticleId><ArticleId IdType="pubmed">33516277</ArticleId></ArticleIdList></Reference><Reference><Citation>Sekine T., Perez-Potti A., Rivera-Ballesteros O., Strålin K., Gorin J.-B., Olsson A., Llewellyn-Lacey S., Kamal H., Bogdanovic G., Muschiol S., et al. Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19. Cell. 2020;183:158–168.e14. doi: 10.1016/j.cell.2020.08.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.08.017</ArticleId><ArticleId IdType="pmc">PMC7427556</ArticleId><ArticleId IdType="pubmed">32979941</ArticleId></ArticleIdList></Reference><Reference><Citation>McMahan K., Yu J., Mercado N.B., Loos C., Tostanoski L.H., Chandrashekar A., Liu J., Peter L., Atyeo C., Zhu A., et al. Correlates of Protection against SARS-CoV-2 in Rhesus Macaques. Nature. 2021;590:630–634. doi: 10.1038/s41586-020-03041-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-03041-6</ArticleId><ArticleId IdType="pmc">PMC7906955</ArticleId><ArticleId IdType="pubmed">33276369</ArticleId></ArticleIdList></Reference><Reference><Citation>Markov N.S., Ren Z., Senkow K.J., Grant R.A., Gao C.A., Malsin E.S., Sichizya L., Kihshen H., Helmin K.A., Jovisic M., et al. Distinctive evolution of alveolar T cell responses is associated with clinical outcomes in unvaccinated patients with SARS-CoV-2 pneumonia. Nat. Immunol. 2024;25:1607–1622. doi: 10.1038/s41590-024-01914-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-024-01914-w</ArticleId><ArticleId IdType="pmc">PMC11490290</ArticleId><ArticleId IdType="pubmed">39138384</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Q., Zhang L., Kuwahara K., Li L., Liu Z., Li T., Zhu H., Liu J., Xu Y., Xie J., et al. Immunodominant SARS Coronavirus Epitopes in Humans Elicited Both Enhancing and Neutralizing Effects on Infection in Non-Human Primates. ACS Infect. Dis. 2016;2:361–376. doi: 10.1021/acsinfecdis.6b00006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acsinfecdis.6b00006</ArticleId><ArticleId IdType="pmc">PMC7075522</ArticleId><ArticleId IdType="pubmed">27627203</ArticleId></ArticleIdList></Reference><Reference><Citation>Zayou L., Prakash S., Dhanushkodi N.R., Quadiri A., Ibraim I.C., Singer M., Salem A., Shaik A.M., Suzer B., Chilukuri A., et al. A Multi-Epitope/CXCL11 Prime/Pull Coronavirus Mucosal Vaccine Boosts the Frequency and the Function of Lung-Resident Memory CD4+ and CD8+ T Cells and Enhanced Protection against COVID-19-like Symptoms and Death Caused by SARS-CoV-2 Infection. J. Virol. 2023;97:e01096-23. doi: 10.1128/jvi.01096-23.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/jvi.01096-23</ArticleId><ArticleId IdType="pmc">PMC10734477</ArticleId><ArticleId IdType="pubmed">38038432</ArticleId></ArticleIdList></Reference><Reference><Citation>Abdelaziz M.O., Raftery M.J., Weihs J., Bielawski O., Edel R., Köppke J., Vladimirova D., Adler J.M., Firsching T., Voß A., et al. Early Protective Effect of a (“Pan”) Coronavirus Vaccine (PanCoVac) in Roborovski Dwarf Hamsters after Single-Low Dose Intranasal Administration. Front. Immunol. 2023;14:1166765. doi: 10.3389/fimmu.2023.1166765.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2023.1166765</ArticleId><ArticleId IdType="pmc">PMC10372429</ArticleId><ArticleId IdType="pubmed">37520530</ArticleId></ArticleIdList></Reference><Reference><Citation>Perdiguero B., Marcos-Villar L., López-Bravo M., Sánchez-Cordón P.J., Zamora C., Valverde J.R., Sorzano C.Ó.S., Sin L., Álvarez E., Ramos M., et al. Immunogenicity and Efficacy of a Novel Multi-Patch SARS-CoV-2/COVID-19 Vaccine Candidate. Front. Immunol. 2023;14:1160065. doi: 10.3389/fimmu.2023.1160065.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2023.1160065</ArticleId><ArticleId IdType="pmc">PMC10316789</ArticleId><ArticleId IdType="pubmed">37404819</ArticleId></ArticleIdList></Reference><Reference><Citation>Arieta C.M., Xie Y.J., Rothenberg D.A., Diao H., Harjanto D., Meda S., Marquart K., Koenitzer B., Sciuto T.E., Lobo A., et al. The T-Cell-Directed Vaccine BNT162b4 Encoding Conserved Non-Spike Antigens Protects Animals from Severe SARS-CoV-2 Infection. Cell. 2023;186:2392–2409.e21. doi: 10.1016/j.cell.2023.04.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2023.04.007</ArticleId><ArticleId IdType="pmc">PMC10099181</ArticleId><ArticleId IdType="pubmed">37164012</ArticleId></ArticleIdList></Reference><Reference><Citation>Boulton S., Poutou J., Gill R., Alluqmani N., He X., Singaravelu R., Crupi M.J.F., Petryk J., Austin B., Angka L., et al. A T Cell-Targeted Multi-Antigen Vaccine Generates Robust Cellular and Humoral Immunity against SARS-CoV-2 Infection. Mol. Ther. Methods Clin. Dev. 2023;31:101110. doi: 10.1016/j.omtm.2023.101110.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.omtm.2023.101110</ArticleId><ArticleId IdType="pmc">PMC10562195</ArticleId><ArticleId IdType="pubmed">37822719</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang C.Y., Kuo B.-S., Lee Y.-H., Ho Y.-H., Pan Y.-H., Yang Y.-T., Chang H.-C., Fu L.-F., Peng W.-J. UB-612 Pan-SARS-CoV-2 T Cell Immunity-Promoting Vaccine Protects against COVID-19 Moderate-Severe Disease. iScience. 2024;27:108887. doi: 10.1016/j.isci.2024.108887.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.isci.2024.108887</ArticleId><ArticleId IdType="pmc">PMC10839960</ArticleId><ArticleId IdType="pubmed">38318376</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang S., Wang C.Y., Kuo H.-K., Peng W.-J., Huang J.-H., Kuo B.-S., Lin F., Liu Y.-J., Liu Z., Wu H.-T., et al. A Novel RBD-Protein/Peptide Vaccine Elicits Broadly Neutralizing Antibodies and Protects Mice and Macaques against SARS-CoV-2. Emerg. Microbes Infect. 2022;11:2724–2734. doi: 10.1080/22221751.2022.2140608.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/22221751.2022.2140608</ArticleId><ArticleId IdType="pmc">PMC9662039</ArticleId><ArticleId IdType="pubmed">36287714</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang C.Y., Hwang K.-P., Kuo H.-K., Peng W.-J., Shen Y.-H., Kuo B.-S., Huang J.-H., Liu H., Ho Y.-H., Lin F., et al. A Multitope SARS-CoV-2 Vaccine Provides Long-Lasting B Cell and T Cell Immunity against Delta and Omicron Variants. J. Clin. Investig. 2022;132:e157707. doi: 10.1172/JCI157707.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI157707</ArticleId><ArticleId IdType="pmc">PMC9106357</ArticleId><ArticleId IdType="pubmed">35316221</ArticleId></ArticleIdList></Reference><Reference><Citation>Heitmann J.S., Tandler C., Marconato M., Nelde A., Habibzada T., Rittig S.M., Tegeler C.M., Maringer Y., Jaeger S.U., Denk M., et al. Phase I/II Trial of a Peptide-Based COVID-19 T-Cell Activator in Patients with B-Cell Deficiency. Nat. Commun. 2023;14:5032. doi: 10.1038/s41467-023-40758-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-023-40758-0</ArticleId><ArticleId IdType="pmc">PMC10439231</ArticleId><ArticleId IdType="pubmed">37596280</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen J., Wang P., Yuan L., Zhang L., Zhang L., Zhao H., Chen C., Wang X., Han J., Chen Y., et al. A Live Attenuated Virus-Based Intranasal COVID-19 Vaccine Provides Rapid, Prolonged, and Broad Protection against SARS-CoV-2. Sci. Bull. 2022;67:1372–1387. doi: 10.1016/j.scib.2022.05.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.scib.2022.05.018</ArticleId><ArticleId IdType="pmc">PMC9134758</ArticleId><ArticleId IdType="pubmed">35637645</ArticleId></ArticleIdList></Reference><Reference><Citation>Loes A.N., Gentles L.E., Greaney A.J., Crawford K.H.D., Bloom J.D. Attenuated Influenza Virions Expressing the SARS-CoV-2 Receptor-Binding Domain Induce Neutralizing Antibodies in Mice. Viruses. 2020;12:987. doi: 10.3390/v12090987.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v12090987</ArticleId><ArticleId IdType="pmc">PMC7552029</ArticleId><ArticleId IdType="pubmed">32899480</ArticleId></ArticleIdList></Reference><Reference><Citation>Koonpaew S., Kaewborisuth C., Srisutthisamphan K., Wanitchang A., Thaweerattanasinp T., Saenboonrueng J., Poonsuk S., Jengarn J., Viriyakitkosol R., Kramyu J., et al. A Single-Cycle Influenza A Virus-Based SARS-CoV-2 Vaccine Elicits Potent Immune Responses in a Mouse Model. Vaccines. 2021;9:850. doi: 10.3390/vaccines9080850.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines9080850</ArticleId><ArticleId IdType="pmc">PMC8402467</ArticleId><ArticleId IdType="pubmed">34451975</ArticleId></ArticleIdList></Reference><Reference><Citation>Chaparian R.R., Harding A.T., Hamele C.E., Riebe K., Karlsson A., Sempowski G.D., Heaton N.S., Heaton B.E. A Virion-Based Combination Vaccine Protects against Influenza and SARS-CoV-2 Disease in Mice. J. Virol. 2022;96:e00689-22. doi: 10.1128/jvi.00689-22.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/jvi.00689-22</ArticleId><ArticleId IdType="pmc">PMC9364787</ArticleId><ArticleId IdType="pubmed">35862698</ArticleId></ArticleIdList></Reference><Reference><Citation>Moser M.J., Hill-Batorski L., Bowen R.A., Matejka S.M., Marshall D., Kawaoka Y., Neumann G., Bilsel P. Intranasal Single-Replication Influenza Vector Induces Cross-Reactive Serum and Mucosal Antibodies against SARS-CoV-2 Variants. Vaccines. 2023;11:1063. doi: 10.3390/vaccines11061063.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines11061063</ArticleId><ArticleId IdType="pmc">PMC10302585</ArticleId><ArticleId IdType="pubmed">37376452</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao Y., Zhao L., Li Y., Liu Q., Deng L., Lu Y., Zhang X., Li S., Ge J., Bu Z., et al. An Influenza Virus Vector Candidate Vaccine Stably Expressing SARS-CoV-2 Receptor-Binding Domain Produces High and Long-Lasting Neutralizing Antibodies in Mice. Vet. Microbiol. 2022;271:109491. doi: 10.1016/j.vetmic.2022.109491.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vetmic.2022.109491</ArticleId><ArticleId IdType="pmc">PMC9181763</ArticleId><ArticleId IdType="pubmed">35714529</ArticleId></ArticleIdList></Reference><Reference><Citation>Isakova-Sivak I., Stepanova E., Matyushenko V., Niskanen S., Mezhenskaya D., Bazhenova E., Krutikova E., Kotomina T., Prokopenko P., Neterebskii B., et al. Development of a T Cell-Based COVID-19 Vaccine Using a Live Attenuated Influenza Vaccine Viral Vector. Vaccines. 2022;10:1142. doi: 10.3390/vaccines10071142.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines10071142</ArticleId><ArticleId IdType="pmc">PMC9318028</ArticleId><ArticleId IdType="pubmed">35891306</ArticleId></ArticleIdList></Reference><Reference><Citation>Boonnak K., Paskel M., Matsuoka Y., Vogel L., Subbarao K. Evaluation of Replication, Immunogenicity and Protective Efficacy of a Live Attenuated Cold-Adapted Pandemic H1N1 Influenza Virus Vaccine in Non-Human Primates. Vaccine. 2012;30:5603–5610. doi: 10.1016/j.vaccine.2012.06.088.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2012.06.088</ArticleId><ArticleId IdType="pmc">PMC3412900</ArticleId><ArticleId IdType="pubmed">22789506</ArticleId></ArticleIdList></Reference><Reference><Citation>Skinner J.A., Zurawski S.M., Sugimoto C., Vinet-Oliphant H., Vinod P., Xue Y., Russell-Lodrigue K., Albrecht R.A., García-Sastre A., Salazar A.M., et al. Immunologic Characterization of a Rhesus Macaque H1N1 Challenge Model for Candidate Influenza Virus Vaccine Assessment. Clin. Vaccine Immunol. 2014;21:1668–1680. doi: 10.1128/CVI.00547-14.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/CVI.00547-14</ArticleId><ArticleId IdType="pmc">PMC4248778</ArticleId><ArticleId IdType="pubmed">25298110</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan M., Tiwary M., Wu H.L., Tailor N., Vendramelli R., Audet J., Warner B.M., Tierney K., Albietz A., Truong T., et al. Pandemic 1918 Influenza Virus Does Not Cause Lethal Infection in Rhesus or Cynomolgus Macaques. J. Virol. 2022;96:e00728-22. doi: 10.1128/jvi.00728-22.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/jvi.00728-22</ArticleId><ArticleId IdType="pmc">PMC9400491</ArticleId><ArticleId IdType="pubmed">35924920</ArticleId></ArticleIdList></Reference><Reference><Citation>Berendt R.F., McDonough W.E., Walker J.S. Persistence of Diplococcus Pneumoniae after Influenza Virus Infection in Macaca mulatta. Infect. Immun. 1974;10:369–374. doi: 10.1128/iai.10.2.369-374.1974.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/iai.10.2.369-374.1974</ArticleId><ArticleId IdType="pmc">PMC415007</ArticleId><ArticleId IdType="pubmed">4152991</ArticleId></ArticleIdList></Reference><Reference><Citation>Berendt R.F. Simian Model for the Evaluation of Immunity to Influenza. Infect. Immun. 1974;9:101–105. doi: 10.1128/iai.9.1.101-105.1974.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/iai.9.1.101-105.1974</ArticleId><ArticleId IdType="pmc">PMC414772</ArticleId><ArticleId IdType="pubmed">4202882</ArticleId></ArticleIdList></Reference><Reference><Citation>Short S.J., Lubach G.R., Karasin A.I., Olsen C.W., Styner M., Knickmeyer R.C., Gilmore J.H., Coe C.L. Maternal Influenza Infection During Pregnancy Impacts Postnatal Brain Development in the Rhesus Monkey. Biol. Psychiatry. 2010;67:965–973. doi: 10.1016/j.biopsych.2009.11.026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biopsych.2009.11.026</ArticleId><ArticleId IdType="pmc">PMC3235476</ArticleId><ArticleId IdType="pubmed">20079486</ArticleId></ArticleIdList></Reference><Reference><Citation>McCarthy K.R., Von Holle T.A., Sutherland L.L., Oguin T.H., Sempowski G.D., Harrison S.C., Moody M.A. Differential Immune Imprinting by Influenza Virus Vaccination and Infection in Nonhuman Primates. Proc. Natl. Acad. Sci. USA. 2021;118:e2026752118. doi: 10.1073/pnas.2026752118.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2026752118</ArticleId><ArticleId IdType="pmc">PMC8201799</ArticleId><ArticleId IdType="pubmed">34074774</ArticleId></ArticleIdList></Reference><Reference><Citation>Shinya K., Gao Y., Cilloniz C., Suzuki Y., Fujie M., Deng G., Zhu Q., Fan S., Makino A., Muramoto Y., et al. Integrated Clinical, Pathologic, Virologic, and Transcriptomic Analysis of H5N1 Influenza Virus-Induced Viral Pneumonia in the Rhesus Macaque. J. Virol. 2012;86:6055–6066. doi: 10.1128/JVI.00365-12.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00365-12</ArticleId><ArticleId IdType="pmc">PMC3372212</ArticleId><ArticleId IdType="pubmed">22491448</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis A.S., Taubenberger J.K., Bray M. The Use of Nonhuman Primates in Research on Seasonal, Pandemic and Avian Influenza, 1893–2014. Antivir. Res. 2015;117:75–98. doi: 10.1016/j.antiviral.2015.02.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2015.02.011</ArticleId><ArticleId IdType="pmc">PMC4462516</ArticleId><ArticleId IdType="pubmed">25746173</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng H., Li H., Guo L., Liang Y., Li J., Wang X., Hu Y., Wang L., Liao Y., Yang F., et al. Virulence and Pathogenesis of SARS-CoV-2 Infection in Rhesus Macaques: A Nonhuman Primate Model of COVID-19 Progression. PLoS Pathog. 2020;16:e1008949. doi: 10.1371/journal.ppat.1008949.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1008949</ArticleId><ArticleId IdType="pmc">PMC7660522</ArticleId><ArticleId IdType="pubmed">33180882</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu S., Zhao Y., Yu W., Yang Y., Gao J., Wang J., Kuang D., Yang M., Yang J., Ma C., et al. Comparison of Nonhuman Primates Identified the Suitable Model for COVID-19. Signal Transduct. Target. Ther. 2020;5:157. doi: 10.1038/s41392-020-00269-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41392-020-00269-6</ArticleId><ArticleId IdType="pmc">PMC7434851</ArticleId><ArticleId IdType="pubmed">32814760</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao Q., Bao L., Mao H., Wang L., Xu K., Yang M., Li Y., Zhu L., Wang N., Lv Z., et al. Development of an Inactivated Vaccine Candidate for SARS-CoV-2. Science. 2020;369:77–81. doi: 10.1126/science.abc1932.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abc1932</ArticleId><ArticleId IdType="pmc">PMC7202686</ArticleId><ArticleId IdType="pubmed">32376603</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu P., Qi F., Xu Y., Li F., Liu P., Liu J., Bao L., Deng W., Gao H., Xiang Z., et al. Age-related Rhesus Macaque Models of COVID-19. Anim. Models Exp. Med. 2020;3:93–97. doi: 10.1002/ame2.12108.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ame2.12108</ArticleId><ArticleId IdType="pmc">PMC7167234</ArticleId><ArticleId IdType="pubmed">32318665</ArticleId></ArticleIdList></Reference><Reference><Citation>Witt A.N., Green R.D., Winterborn A.N. A Meta-Analysis of Rhesus Macaques (Macaca mulatta), Cynomolgus Macaques (Macaca fascicularis), African Green Monkeys (Chlorocebus aethiops), and Ferrets (Mustela putorius furo) as Large Animal Models for COVID-19. Comp. Med. 2021;71:433–441. doi: 10.30802/AALAS-CM-21-000032.</Citation><ArticleIdList><ArticleId IdType="doi">10.30802/AALAS-CM-21-000032</ArticleId><ArticleId IdType="pmc">PMC8594258</ArticleId><ArticleId IdType="pubmed">34588096</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu J., Tostanoski L.H., Peter L., Mercado N.B., McMahan K., Mahrokhian S.H., Nkolola J.P., Liu J., Li Z., Chandrashekar A., et al. DNA Vaccine Protection against SARS-CoV-2 in Rhesus Macaques. Science. 2020;369:806–811. doi: 10.1126/science.abc6284.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abc6284</ArticleId><ArticleId IdType="pmc">PMC7243363</ArticleId><ArticleId IdType="pubmed">32434945</ArticleId></ArticleIdList></Reference><Reference><Citation>Vogel A.B., Kanevsky I., Che Y., Swanson K.A., Muik A., Vormehr M., Kranz L.M., Walzer K.C., Hein S., Güler A., et al. BNT162b Vaccines Protect Rhesus Macaques from SARS-CoV-2. Nature. 2021;592:283–289. doi: 10.1038/s41586-021-03275-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03275-y</ArticleId><ArticleId IdType="pubmed">33524990</ArticleId></ArticleIdList></Reference><Reference><Citation>Mercado N.B., Zahn R., Wegmann F., Loos C., Chandrashekar A., Yu J., Liu J., Peter L., McMahan K., Tostanoski L.H., et al. Single-Shot Ad26 Vaccine Protects against SARS-CoV-2 in Rhesus Macaques. Nature. 2020;586:583. doi: 10.1038/s41586-020-2607-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2607-z</ArticleId><ArticleId IdType="pmc">PMC7581548</ArticleId><ArticleId IdType="pubmed">32731257</ArticleId></ArticleIdList></Reference><Reference><Citation>Tseng C.-T., Sbrana E., Iwata-Yoshikawa N., Newman P.C., Garron T., Atmar R.L., Peters C.J., Couch R.B. Immunization with SARS Coronavirus Vaccines Leads to Pulmonary Immunopathology on Challenge with the SARS Virus. PLoS ONE. 2012;7:e35421. doi: 10.1371/annotation/2965cfae-b77d-4014-8b7b-236e01a35492.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/annotation/2965cfae-b77d-4014-8b7b-236e01a35492</ArticleId><ArticleId IdType="pmc">PMC3335060</ArticleId><ArticleId IdType="pubmed">22536382</ArticleId></ArticleIdList></Reference><Reference><Citation>Bigay J., Le Grand R., Martinon F., Maisonnasse P. Vaccine-Associated Enhanced Disease in Humans and Animal Models: Lessons and Challenges for Vaccine Development. Front. Microbiol. 2022;13:932408. doi: 10.3389/fmicb.2022.932408.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmicb.2022.932408</ArticleId><ArticleId IdType="pmc">PMC9399815</ArticleId><ArticleId IdType="pubmed">36033843</ArticleId></ArticleIdList></Reference><Reference><Citation>Ebenig A., Muraleedharan S., Kazmierski J., Todt D., Auste A., Anzaghe M., Gömer A., Postmus D., Gogesch P., Niles M., et al. Vaccine-Associated Enhanced Respiratory Pathology in COVID-19 Hamsters after TH2-Biased Immunization. Cell Rep. 2022;40:111214. doi: 10.1016/j.celrep.2022.111214.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2022.111214</ArticleId><ArticleId IdType="pmc">PMC9346010</ArticleId><ArticleId IdType="pubmed">35952673</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang T., Magazine N., McGee M.C., Carossino M., Veggiani G., Kousoulas K.G., August A., Huang W. Th2 and Th17-Associated Immunopathology Following SARS-CoV-2 Breakthrough Infection in Spike-Vaccinated ACE2-Humanized Mice. J. Med. Virol. 2024;96:e29408. doi: 10.1002/jmv.29408.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.29408</ArticleId><ArticleId IdType="pmc">PMC10832989</ArticleId><ArticleId IdType="pubmed">38258331</ArticleId></ArticleIdList></Reference><Reference><Citation>Matyushenko V., Isakova-Sivak I., Kudryavtsev I., Goshina A., Chistyakova A., Stepanova E., Prokopenko P., Sychev I., Rudenko L. Detection of IFNγ-Secreting CD4+ and CD8+ Memory T Cells in COVID-19 Convalescents after Stimulation of Peripheral Blood Mononuclear Cells with Live SARS-CoV-2. Viruses. 2021;13:1490. doi: 10.3390/v13081490.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v13081490</ArticleId><ArticleId IdType="pmc">PMC8402842</ArticleId><ArticleId IdType="pubmed">34452355</ArticleId></ArticleIdList></Reference><Reference><Citation>Rak A., Gorbunov N., Kostevich V., Sokolov A., Prokopenko P., Rudenko L., Isakova-Sivak I. Assessment of Immunogenic and Antigenic Properties of Recombinant Nucleocapsid Proteins of Five SARS-CoV-2 Variants in a Mouse Model. Viruses. 2023;15:230. doi: 10.3390/v15010230.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v15010230</ArticleId><ArticleId IdType="pmc">PMC9861333</ArticleId><ArticleId IdType="pubmed">36680269</ArticleId></ArticleIdList></Reference><Reference><Citation>Reed L.J., Muench H. A Simple Method of Estimating Fifty per Cent Endpoints. Am. J. Epidemiol. 1938;27:493–497. doi: 10.1093/oxfordjournals.aje.a118408.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/oxfordjournals.aje.a118408</ArticleId></ArticleIdList></Reference><Reference><Citation>Directive 2010/63/EU of the European Parliament and of the Council of September 22, 2010, on the Protection of Animals Used for Scientific Purposes. 2010.  [(accessed on 24 September 2024)].  Available online:  https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=celex%3A32010L0063.</Citation></Reference><Reference><Citation>Shu B., Wu K.-H., Emery S., Villanueva J., Johnson R., Guthrie E., Berman L., Warnes C., Barnes N., Klimov A., et al. Design and Performance of the CDC Real-Time Reverse Transcriptase PCR Swine Flu Panel for Detection of 2009 A (H1N1) Pandemic Influenza Virus. J. Clin. Microbiol. 2011;49:2614–2619. doi: 10.1128/JCM.02636-10.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JCM.02636-10</ArticleId><ArticleId IdType="pmc">PMC3147828</ArticleId><ArticleId IdType="pubmed">21593260</ArticleId></ArticleIdList></Reference><Reference><Citation>Matyushenko V., Isakova-Sivak I., Smolonogina T., Dubrovina I., Tretiak T., Rudenko L. Genotyping Assay for Differentiation of Wild-Type and Vaccine Viruses in Subjects Immunized with Live Attenuated Influenza Vaccine. PLoS ONE. 2017;12:e0180497. doi: 10.1371/journal.pone.0180497.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0180497</ArticleId><ArticleId IdType="pmc">PMC5501548</ArticleId><ArticleId IdType="pubmed">28686625</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization . WHO Manual on Animal Influenza Diagnosis and Surveillance. WHO; Geneva, Switzerland: 2002.</Citation></Reference><Reference><Citation>Reactivity Database.  [(accessed on 10 June 2024)].  Available online:  https://www.nhpreagents.org/ReactivityDatabase.</Citation></Reference><Reference><Citation>Magalhaes I., Vudattu N.K., Ahmed R.K., Kühlmann-Berenzon S., Ngo Y., Sizemore D.R., Wehlin L., Weichold F., Andersson J., Skeiky Y.A., et al. High Content Cellular Immune Profiling Reveals Differences between Rhesus Monkeys and Men. Immunology. 2010;131:128–140. doi: 10.1111/j.1365-2567.2010.03284.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2567.2010.03284.x</ArticleId><ArticleId IdType="pmc">PMC2966765</ArticleId><ArticleId IdType="pubmed">20465573</ArticleId></ArticleIdList></Reference><Reference><Citation>Bjornson-Hooper Z.B., Fragiadakis G.K., Spitzer M.H., Chen H., Madhireddy D., Hu K., Lundsten K., McIlwain D.R., Nolan G.P. A Comprehensive Atlas of Immunological Differences between Humans, Mice, and Non-Human Primates. Front. Immunol. 2022;13:867015. doi: 10.3389/fimmu.2022.867015.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.867015</ArticleId><ArticleId IdType="pmc">PMC8962947</ArticleId><ArticleId IdType="pubmed">35359965</ArticleId></ArticleIdList></Reference><Reference><Citation>Pitcher C.J., Hagen S.I., Walker J.M., Lum R., Mitchell B.L., Maino V.C., Axthelm M.K., Picker L.J. Development and Homeostasis of T Cell Memory in Rhesus Macaque. J. Immunol. 2002;168:29–43. doi: 10.4049/jimmunol.168.1.29.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.168.1.29</ArticleId><ArticleId IdType="pubmed">11751943</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO  Recommendations to Assure the Quality, Safety and Efficacy of Influenza Vaccines (Human, Live Attenuated) for Intranasal Administration, Annex 4, TRS No 977.  [(accessed on 5 September 2024)].  Available online:  https://www.who.int/publications/m/item/influenza-attenuated-intranasal-administration-annex-4-trs-no-977.</Citation></Reference><Reference><Citation>Kiseleva I., Su Q., Toner T.J., Szymkowiak C., Kwan W.-S., Rudenko L., Shaw A.R., Youil R. Cell-Based Assay for the Determination of Temperature Sensitive and Cold Adapted Phenotypes of Influenza Viruses. J. Virol. Methods. 2004;116:71–78. doi: 10.1016/j.jviromet.2003.10.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jviromet.2003.10.012</ArticleId><ArticleId IdType="pubmed">14715309</ArticleId></ArticleIdList></Reference><Reference><Citation>Isakova-Sivak I., Chen L.-M., Matsuoka Y., Voeten J.T.M., Kiseleva I., Heldens J.G.M., van den Bosch H., Klimov A., Rudenko L., Cox N.J., et al. Genetic Bases of the Temperature-Sensitive Phenotype of a Master Donor Virus Used in Live Attenuated Influenza Vaccines: A/Leningrad/134/17/57 (H2N2) Virology. 2011;412:297–305. doi: 10.1016/j.virol.2011.01.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virol.2011.01.004</ArticleId><ArticleId IdType="pubmed">21315402</ArticleId></ArticleIdList></Reference><Reference><Citation>Serum Institute of India Pvt. Ltd  . Nasovac-S Influenza Vaccine, Live, Attenuated (Human) [Package Insert] Serum Institute of India Pvt. Ltd.; Pune, India: Feb, 2021.  [(accessed on 24 September 2024)].  Available online:  https://extranet.who.int/prequal/sites/default/files/vwa_vaccine/pq_297_Nasovac-S_1dose_SII_PI_NH-2021.pdf.</Citation></Reference><Reference><Citation>Grohskopf L.A. Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices—United States, 2023–24 Influenza Season. MMWR Recomm. Rep. 2023;72:1–25. doi: 10.15585/mmwr.rr7202a1.</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.rr7202a1</ArticleId><ArticleId IdType="pmc">PMC11501009</ArticleId><ArticleId IdType="pubmed">39197095</ArticleId></ArticleIdList></Reference><Reference><Citation>Isakova-Sivak I., Matyushenko V., Stepanova E., Matushkina A., Kotomina T., Mezhenskaya D., Prokopenko P., Kudryavtsev I., Kopeykin P., Sivak K., et al. Recombinant Live Attenuated Influenza Vaccine Viruses Carrying Conserved T-Cell Epitopes of Human Adenoviruses Induce Functional Cytotoxic T-Cell Responses and Protect Mice against Both Infections. Vaccines. 2020;8:196. doi: 10.3390/vaccines8020196.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines8020196</ArticleId><ArticleId IdType="pmc">PMC7349758</ArticleId><ArticleId IdType="pubmed">32344618</ArticleId></ArticleIdList></Reference><Reference><Citation>Kotomina T., Korenkov D., Matyushenko V., Prokopenko P., Rudenko L., Isakova-Sivak I. Live Attenuated Influenza Vaccine Viral Vector Induces Functional Cytotoxic T-Cell Immune Response against Foreign CD8+ T-Cell Epitopes Inserted into NA and NS1 Genes Using the 2A Self-Cleavage Site. Hum. Vaccines Immunother. 2018;14:2964–2970. doi: 10.1080/21645515.2018.1502529.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21645515.2018.1502529</ArticleId><ArticleId IdType="pmc">PMC6343631</ArticleId><ArticleId IdType="pubmed">30024831</ArticleId></ArticleIdList></Reference><Reference><Citation>Matyushenko V., Kotomina T., Kudryavtsev I., Mezhenskaya D., Prokopenko P., Matushkina A., Sivak K., Muzhikyan A., Rudenko L., Isakova-Sivak I. Conserved T-Cell Epitopes of Respiratory Syncytial Virus (RSV) Delivered by Recombinant Live Attenuated Influenza Vaccine Viruses Efficiently Induce RSV-Specific Lung-Localized Memory T Cells and Augment Influenza-Specific Resident Memory T-Cell Responses. Antivir. Res. 2020;182:104864. doi: 10.1016/j.antiviral.2020.104864.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2020.104864</ArticleId><ArticleId IdType="pmc">PMC7313889</ArticleId><ArticleId IdType="pubmed">32585323</ArticleId></ArticleIdList></Reference><Reference><Citation>Mooij P., Balla-Jhagjhoorsingh S.S., Beenhakker N., van Haaften P., Baak I., Nieuwenhuis I.G., Heidari S., Wolf H., Frachette M.-J., Bieler K., et al. Comparison of Human and Rhesus Macaque T-Cell Responses Elicited by Boosting with NYVAC Encoding Human Immunodeficiency Virus Type 1 Clade C Immunogens. J. Virol. 2009;83:5881–5889. doi: 10.1128/JVI.02345-08.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.02345-08</ArticleId><ArticleId IdType="pmc">PMC2681993</ArticleId><ArticleId IdType="pubmed">19321612</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccari M., Franchini G. Memory T Cells in Rhesus Macaques. Adv. Exp. Med. Biol. 2010;684:126–144. doi: 10.1007/978-1-4419-6451-9_10.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-1-4419-6451-9_10</ArticleId><ArticleId IdType="pmc">PMC7316376</ArticleId><ArticleId IdType="pubmed">20795545</ArticleId></ArticleIdList></Reference><Reference><Citation>Burel J.G., Apte S.H., Groves P.L., McCarthy J.S., Doolan D.L. Polyfunctional and IFN-γ Monofunctional Human CD4+ T Cell Populations Are Molecularly Distinct. JCI Insight. 2017;2:e87499. doi: 10.1172/jci.insight.87499.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci.insight.87499</ArticleId><ArticleId IdType="pmc">PMC5291737</ArticleId><ArticleId IdType="pubmed">28194431</ArticleId></ArticleIdList></Reference><Reference><Citation>Imai N., Tawara I., Yamane M., Muraoka D., Shiku H., Ikeda H. CD4+ T Cells Support Polyfunctionality of Cytotoxic CD8+ T Cells with Memory Potential in Immunological Control of Tumor. Cancer Sci. 2020;111:1958–1968. doi: 10.1111/cas.14420.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/cas.14420</ArticleId><ArticleId IdType="pmc">PMC7293103</ArticleId><ArticleId IdType="pubmed">32304127</ArticleId></ArticleIdList></Reference><Reference><Citation>Jacob-Dolan C., Yu J., McMahan K., Giffin V., Chandrashekar A., Martinot A.J., Anioke T., Powers O.C., Hall K., Hope D., et al. Immunogenicity and Protective Efficacy of GBP510/AS03 Vaccine against SARS-CoV-2 Delta Challenge in Rhesus Macaques. NPJ Vaccines. 2023;8:23. doi: 10.1038/s41541-023-00622-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41541-023-00622-0</ArticleId><ArticleId IdType="pmc">PMC9947939</ArticleId><ArticleId IdType="pubmed">36823160</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao G., Hu X., Zhou Y., Rao J., Zhang X., Peng Y., Zhao J., Yao Y., Liu K., Liang M., et al. Infection and Pathogenesis of the Delta Variant of SARS-CoV-2 in Rhesus Macaque. Virol. Sin. 2022;37:299–302. doi: 10.1016/j.virs.2022.02.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virs.2022.02.001</ArticleId><ArticleId IdType="pmc">PMC8828374</ArticleId><ArticleId IdType="pubmed">35279412</ArticleId></ArticleIdList></Reference><Reference><Citation>Gagne M., Corbett K.S., Flynn B.J., Foulds K.E., Wagner D.A., Andrew S.F., Todd J.-P.M., Honeycutt C.C., McCormick L., Nurmukhambetova S.T., et al. Protection from SARS-CoV-2 Delta One Year after mRNA-1273 Vaccination in Rhesus Macaques Coincides with Anamnestic Antibody Response in the Lung. Cell. 2022;185:113–130.e15. doi: 10.1016/j.cell.2021.12.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2021.12.002</ArticleId><ArticleId IdType="pmc">PMC8639396</ArticleId><ArticleId IdType="pubmed">34921774</ArticleId></ArticleIdList></Reference><Reference><Citation>Salguero F.J., White A.D., Slack G.S., Fotheringham S.A., Bewley K.R., Gooch K.E., Longet S., Humphries H.E., Watson R.J., Hunter L., et al. Comparison of Rhesus and Cynomolgus Macaques as an Infection Model for COVID-19. Nat. Commun. 2021;12:1260. doi: 10.1038/s41467-021-21389-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-021-21389-9</ArticleId><ArticleId IdType="pmc">PMC7904795</ArticleId><ArticleId IdType="pubmed">33627662</ArticleId></ArticleIdList></Reference><Reference><Citation>Routhu N.K., Gangadhara S., Lai L., Davis Gardner M.E., Floyd K., Shiferaw A., Bartsch Y.C., Fischinger S., Khoury G., Rahman S.A., et al. A Modified Vaccinia Ankara Vaccine Expressing Spike and Nucleocapsid Protects Rhesus Macaques against SARS-CoV-2 Delta Infection. Sci. Immunol. 2022;7:eabo0226. doi: 10.1126/sciimmunol.abo0226.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciimmunol.abo0226</ArticleId><ArticleId IdType="pmc">PMC8995033</ArticleId><ArticleId IdType="pubmed">35357886</ArticleId></ArticleIdList></Reference><Reference><Citation>He X., Chandrashekar A., Zahn R., Wegmann F., Yu J., Mercado N.B., McMahan K., Martinot A.J., Piedra-Mora C., Beecy S., et al. Low-Dose Ad26.COV2.S Protection against SARS-CoV-2 Challenge in Rhesus Macaques. Cell. 2021;184:3467–3473.e11. doi: 10.1016/j.cell.2021.05.040.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2021.05.040</ArticleId><ArticleId IdType="pmc">PMC8166510</ArticleId><ArticleId IdType="pubmed">34133941</ArticleId></ArticleIdList></Reference><Reference><Citation>Sui Y., Li J., Zhang R., Prabhu S.K., Andersen H., Venzon D., Cook A., Brown R., Teow E., Velasco J., et al. Protection against SARS-CoV-2 Infection by a Mucosal Vaccine in Rhesus Macaques. JCI Insight. 2021;6:e148494. doi: 10.1172/jci.insight.148494.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci.insight.148494</ArticleId><ArticleId IdType="pmc">PMC8262352</ArticleId><ArticleId IdType="pubmed">33908897</ArticleId></ArticleIdList></Reference><Reference><Citation>van Doremalen N., Lambe T., Spencer A., Belij-Rammerstorfer S., Purushotham J.N., Port J.R., Avanzato V.A., Bushmaker T., Flaxman A., Ulaszewska M., et al. ChAdOx1 nCoV-19 Vaccine Prevents SARS-CoV-2 Pneumonia in Rhesus Macaques. Nature. 2020;586:578–582. doi: 10.1038/s41586-020-2608-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2608-y</ArticleId><ArticleId IdType="pmc">PMC8436420</ArticleId><ArticleId IdType="pubmed">32731258</ArticleId></ArticleIdList></Reference><Reference><Citation>Yadav P.D., Ella R., Kumar S., Patil D.R., Mohandas S., Shete A.M., Vadrevu K.M., Bhati G., Sapkal G., Kaushal H., et al. Immunogenicity and Protective Efficacy of Inactivated SARS-CoV-2 Vaccine Candidate, BBV152 in Rhesus Macaques. Nat. Commun. 2021;12:1386. doi: 10.1038/s41467-021-21639-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-021-21639-w</ArticleId><ArticleId IdType="pmc">PMC7925524</ArticleId><ArticleId IdType="pubmed">33654090</ArticleId></ArticleIdList></Reference><Reference><Citation>Prokopenko P., Matyushenko V., Rak A., Stepanova E., Chistyakova A., Goshina A., Kudryavtsev I., Rudenko L., Isakova-Sivak I. Truncation of NS1 Protein Enhances T Cell-Mediated Cross-Protection of a Live Attenuated Influenza Vaccine Virus Expressing Wild-Type Nucleoprotein. Vaccines. 2023;11:501. doi: 10.3390/vaccines11030501.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines11030501</ArticleId><ArticleId IdType="pmc">PMC10056296</ArticleId><ArticleId IdType="pubmed">36992084</ArticleId></ArticleIdList></Reference><Reference><Citation>Kingstad-Bakke B., Cleven T., Bussan H., Yount B.L., Uraki R., Iwatsuki-Horimoto K., Koga M., Yamamoto S., Yotsuyanagi H., Park H., et al. Airway Surveillance and Lung Viral Control by Memory T Cells Induced by COVID-19 mRNA Vaccine. JCI Insight. 2023;8:e172510. doi: 10.1172/jci.insight.172510.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci.insight.172510</ArticleId><ArticleId IdType="pmc">PMC10721330</ArticleId><ArticleId IdType="pubmed">37796612</ArticleId></ArticleIdList></Reference><Reference><Citation>Blair R.V., Vaccari M., Doyle-Meyers L.A., Roy C.J., Russell-Lodrigue K., Fahlberg M., Monjure C.J., Beddingfield B., Plante K.S., Plante J.A., et al. Acute Respiratory Distress in Aged, SARS-CoV-2–Infected African Green Monkeys but Not Rhesus Macaques. Am. J. Pathol. 2021;191:274–282. doi: 10.1016/j.ajpath.2020.10.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajpath.2020.10.016</ArticleId><ArticleId IdType="pmc">PMC7648506</ArticleId><ArticleId IdType="pubmed">33171111</ArticleId></ArticleIdList></Reference><Reference><Citation>Shan C., Yao Y.-F., Yang X.-L., Zhou Y.-W., Gao G., Peng Y., Yang L., Hu X., Xiong J., Jiang R.-D., et al. Infection with Novel Coronavirus (SARS-CoV-2) Causes Pneumonia in Rhesus Macaques. Cell Res. 2020;30:670–677. doi: 10.1038/s41422-020-0364-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41422-020-0364-z</ArticleId><ArticleId IdType="pmc">PMC7364749</ArticleId><ArticleId IdType="pubmed">32636454</ArticleId></ArticleIdList></Reference><Reference><Citation>van Doremalen N., Singh M., Saturday T.A., Yinda C.K., Perez-Perez L., Bohler W.F., Weishampel Z.A., Lewis M., Schulz J.E., Williamson B.N., et al. SARS-CoV-2 Omicron BA.1 and BA.2 Are Attenuated in Rhesus Macaques as Compared to Delta. Sci. Adv. 2022;8:eade1860. doi: 10.1126/sciadv.ade1860.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciadv.ade1860</ArticleId><ArticleId IdType="pmc">PMC9674298</ArticleId><ArticleId IdType="pubmed">36399566</ArticleId></ArticleIdList></Reference><Reference><Citation>Wan Y., Shang J., Sun S., Tai W., Chen J., Geng Q., He L., Chen Y., Wu J., Shi Z., et al. Molecular Mechanism for Antibody-Dependent Enhancement of Coronavirus Entry. J. Virol. 2020;94:e02015-19. doi: 10.1128/JVI.02015-19.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.02015-19</ArticleId><ArticleId IdType="pmc">PMC7022351</ArticleId><ArticleId IdType="pubmed">31826992</ArticleId></ArticleIdList></Reference><Reference><Citation>Bournazos S., Gupta A., Ravetch J.V. The Role of IgG Fc Receptors in Antibody-Dependent Enhancement. Nat. Rev. Immunol. 2020;20:633–643. doi: 10.1038/s41577-020-00410-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41577-020-00410-0</ArticleId><ArticleId IdType="pmc">PMC7418887</ArticleId><ArticleId IdType="pubmed">32782358</ArticleId></ArticleIdList></Reference><Reference><Citation>Kudryavtsev I., Rubinstein A., Golovkin A., Kalinina O., Vasilyev K., Rudenko L., Isakova-Sivak I. Dysregulated Immune Responses in SARS-CoV-2-Infected Patients: A Comprehensive Overview. Viruses. 2022;14:1082. doi: 10.3390/v14051082.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v14051082</ArticleId><ArticleId IdType="pmc">PMC9147674</ArticleId><ArticleId IdType="pubmed">35632823</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong L.-Y.R., Perlman S. Immune Dysregulation and Immunopathology Induced by SARS-CoV-2 and Related Coronaviruses—Are We Our Own Worst Enemy? Nat. Rev. Immunol. 2022;22:47–56. doi: 10.1038/s41577-021-00656-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41577-021-00656-2</ArticleId><ArticleId IdType="pmc">PMC8617551</ArticleId><ArticleId IdType="pubmed">34837062</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo F., Liao F.-L., Wang H., Tang H.-B., Yang Z.-Q., Hou W. Evaluation of Antibody-Dependent Enhancement of SARS-CoV Infection in Rhesus Macaques Immunized with an Inactivated SARS-CoV Vaccine. Virol. Sin. 2018;33:201–204. doi: 10.1007/s12250-018-0009-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12250-018-0009-2</ArticleId><ArticleId IdType="pmc">PMC6178114</ArticleId><ArticleId IdType="pubmed">29541941</ArticleId></ArticleIdList></Reference><Reference><Citation>Seow J., Graham C., Merrick B., Acors S., Pickering S., Steel K.J.A., Hemmings O., O’Byrne A., Kouphou N., Galao R.P., et al. Longitudinal Observation and Decline of Neutralizing Antibody Responses in the Three Months Following SARS-CoV-2 Infection in Humans. Nat. Microbiol. 2020;5:1598–1607. doi: 10.1038/s41564-020-00813-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41564-020-00813-8</ArticleId><ArticleId IdType="pmc">PMC7610833</ArticleId><ArticleId IdType="pubmed">33106674</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen K.W., Linderman S.L., Moodie Z., Czartoski J., Lai L., Mantus G., Norwood C., Nyhoff L.E., Edara V.V., Floyd K., et al. Longitudinal Analysis Shows Durable and Broad Immune Memory after SARS-CoV-2 Infection with Persisting Antibody Responses and Memory B and T Cells. Cell Rep. Med. 2021;2:100354. doi: 10.1016/j.xcrm.2021.100354.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.xcrm.2021.100354</ArticleId><ArticleId IdType="pmc">PMC8253687</ArticleId><ArticleId IdType="pubmed">34250512</ArticleId></ArticleIdList></Reference><Reference><Citation>Grant E.J., Quiñones-Parra S.M., Clemens E.B., Kedzierska K. Human Influenza Viruses and CD8+ T Cell Responses. Curr. Opin. Virol. 2016;16:132–142. doi: 10.1016/j.coviro.2016.01.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.coviro.2016.01.016</ArticleId><ArticleId IdType="pubmed">26974887</ArticleId></ArticleIdList></Reference><Reference><Citation>Deng W., Bao L., Liu J., Xiao C., Liu J., Xue J., Lv Q., Qi F., Gao H., Yu P., et al. Primary Exposure to SARS-CoV-2 Protects against Reinfection in Rhesus Macaques. Science. 2020;369:eabc5343. doi: 10.1126/science.abc5343.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abc5343</ArticleId><ArticleId IdType="pmc">PMC7402625</ArticleId><ArticleId IdType="pubmed">32616673</ArticleId></ArticleIdList></Reference><Reference><Citation>Chandrashekar A., Liu J., Martinot A.J., McMahan K., Mercado N.B., Peter L., Tostanoski L.H., Yu J., Maliga Z., Nekorchuk M., et al. SARS-CoV-2 Infection Protects against Rechallenge in Rhesus Macaques. Science. 2020;369:812–817. doi: 10.1126/science.abc4776.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abc4776</ArticleId><ArticleId IdType="pmc">PMC7243369</ArticleId><ArticleId IdType="pubmed">32434946</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>